Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
8
0
1

Year Published

1992
1992
2014
2014

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 44 publications
(9 citation statements)
references
References 0 publications
0
8
0
1
Order By: Relevance
“…However, a unique set of intestinal barriers including the stomach's acidic environment, poor permeation of active therapeutics across the thick mucus and epithelial interface, an array of drug degrading intestinal enzymes, and limited retention time due to peristalsis and shear flow conditions limit the overall drug efficacy 1, 2. Although various oral delivery paradigms including enteric‐coated capsules, liposomes, bioadhesive agents, and permeation enhancers were developed, many of these systems are administered with increased frequency on an extended schedule, which is not practical for expensive and/or toxic drugs (chemotherapeutics) 3–11. There are also instances of combination therapy, wherein multiple drugs are to be delivered at the same time for synergistic effects 12.…”
Section: Introductionmentioning
confidence: 99%
“…However, a unique set of intestinal barriers including the stomach's acidic environment, poor permeation of active therapeutics across the thick mucus and epithelial interface, an array of drug degrading intestinal enzymes, and limited retention time due to peristalsis and shear flow conditions limit the overall drug efficacy 1, 2. Although various oral delivery paradigms including enteric‐coated capsules, liposomes, bioadhesive agents, and permeation enhancers were developed, many of these systems are administered with increased frequency on an extended schedule, which is not practical for expensive and/or toxic drugs (chemotherapeutics) 3–11. There are also instances of combination therapy, wherein multiple drugs are to be delivered at the same time for synergistic effects 12.…”
Section: Introductionmentioning
confidence: 99%
“…• Protective coatings have been used to protect the peptide during transport through the acidic environment of the stomach (Saffran et al, 1990) • Bioadhesive agents are used to enhance contact of the peptide to the intestinal wall (Ponchel et al, 1998;Arangoa et al, 2000;Lehr, 2000); • Lipid coatings and polymers are being used to protect peptides and enhance transport across the intestinal wall (Iwanaga et al, 1999) • Local delivery to sites in the GI tract with maximal adsorption and stability (Fara et al, 1985;Davis et al, 1988) • Permeation enhancers are being explored to enhance uptake and transport through the intestinal wall, and protease inhibitors are used to protect peptides from enzymatic degradation (Fasano et al, 1997;Schwarz et al, 2000) While all of these approaches have been shown to increase the oral bioavailability of insulin or other large molecules, none of these approaches offers a complete solution for adequate and safe oral delivery of peptides and proteins. Microfabricated particles may addresses the shortcomings of current oral delivery systems for peptides and proteins by combining the following features into a single drug delivery platform:…”
Section: Microfabricated Oral Delivery Particlesmentioning
confidence: 99%
“…The human gastrointestinal (GI) tract has a naturally low level of permeability since it is designed to resist absorption of peptides, proteins and large molecules until they are broken down into smaller molecules. Several approaches are currently being developed to enhance the oral delivery of macromolecular drugs including protective coatings to protect peptides during trans-port, 1,2 and bioadhesive agents to induce contact of the peptide to the intestinal wall. 3,–5 In addition, the use of permeation enhancers and protease inhibitors to augment uptake and prevent degradation are being explored.…”
Section: Introductionmentioning
confidence: 99%